<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39338402</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1424-8247</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>20</Day></PubDate></JournalIssue><Title>Pharmaceuticals (Basel, Switzerland)</Title><ISOAbbreviation>Pharmaceuticals (Basel)</ISOAbbreviation></Journal><ArticleTitle>Study of Potential Blocking Peptides Targeting the SARS-CoV-2 RBD/hACE2 Interaction.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1240</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ph17091240</ELocationID><Abstract><AbstractText Label="BACKGROUND/OBJECTIVES" NlmCategory="OBJECTIVE">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, was declared a public health emergency in early 2020. The infection initiates when the receptor-binding domain (RBD) of the viral spike protein binds to human angiotensin-converting enzyme 2 (ACE2). Despite the success of vaccination efforts, the emergence of new variants highlights the ongoing need for treatments targeting these evolving strains. In silico methods previously identified peptides BP2, BP9, and BP11 as being capable of disrupting the RBD-ACE2 interaction, though their efficacy has not been experimentally validated until now.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this study, these peptides were recombinantly produced in the yeast <i>Komagataella phaffii</i>, and the activity was assessed in vitro using binding assays with multiple RBD variants and the inhibition of the RBD-ACE2 interaction.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The production yield for BP2, BP9, and BP11 was 14.34, 4.01, and 1.35 mg per culture liter, respectively. Noteworthy, the three BPs interacted with the RBD of SARS-CoV-2 variants of concern, with BP2 showing higher recognition. Finally, the BPs showed an RBD/hACE2 interaction blocking capacity with IC<sub>50</sub> values between 1.03 and 5.35 nM, with BP2 showing the lowest values among the evaluated peptides.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results demonstrate that BP2, specifically, is a promising candidate for the development of novel therapeutic interventions targeting SARS-CoV-2 and other coronaviruses that use hACE2 for cellular entry.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Villada-Troncoso</LastName><ForeName>Sara M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Institute for the Study in Inborn Errors of Metabolism-IEIM, Faculty of Science, Pontificia Universidad Javeriana, Bogotá 110231, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arévalo-Romero</LastName><ForeName>Jenny Andrea</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Institute for the Study in Inborn Errors of Metabolism-IEIM, Faculty of Science, Pontificia Universidad Javeriana, Bogotá 110231, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud-IDCBIS, Bogotá 111611, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernández Rivera</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Unidad de Desarrollo e Investigación en Bioterapéuticos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Prolongación de Carpio y Plan de Ayala S/N, Colonia Santo Tomás, Alcaldía Miguel Hidalgo, Mexico City 11340, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedraza-Escalona</LastName><ForeName>Martha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CONAHCyT-Unidad de Desarrollo e Investigación en Bioterapéuticos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Prolongación de Carpio y Plan de Ayala S/N, Colonia Santo Tomás, Alcaldía Miguel Hidalgo, Mexico City 11340, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pérez-Tapia</LastName><ForeName>Sonia M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0002-2818-8522</Identifier><AffiliationInfo><Affiliation>Unidad de Desarrollo e Investigación en Bioterapéuticos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Prolongación de Carpio y Plan de Ayala S/N, Colonia Santo Tomás, Alcaldía Miguel Hidalgo, Mexico City 11340, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espejo-Mojica</LastName><ForeName>Angela Johana</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0001-9670-6435</Identifier><AffiliationInfo><Affiliation>Institute for the Study in Inborn Errors of Metabolism-IEIM, Faculty of Science, Pontificia Universidad Javeriana, Bogotá 110231, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alméciga-Díaz</LastName><ForeName>Carlos Javier</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0001-6484-1173</Identifier><AffiliationInfo><Affiliation>Institute for the Study in Inborn Errors of Metabolism-IEIM, Faculty of Science, Pontificia Universidad Javeriana, Bogotá 110231, Colombia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>057-2022</GrantID><Agency>Secretaría Distrital de Salud y Agencia ATENEA</Agency><Country /></Grant><Grant><GrantID>activity 120289301011ZZ</GrantID><Agency>Pontificia Universidad Javeriana</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceuticals (Basel)</MedlineTA><NlmUniqueID>101238453</NlmUniqueID><ISSNLinking>1424-8247</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Komagataella phaffii</Keyword><Keyword MajorTopicYN="N">RBD variants</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">blocking peptides</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39338402</ArticleId><ArticleId IdType="pmc">PMC11435355</ArticleId><ArticleId IdType="doi">10.3390/ph17091240</ArticleId><ArticleId IdType="pii">ph17091240</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arevalo-Romero J.A., Chingate-Lopez S.M., Camacho B.A., Almeciga-Diaz C.J., Ramirez-Segura C.A. Next-generation treatments: Immunotherapy and advanced therapies for COVID-19. Heliyon. 2024;10:e26423. doi: 10.1016/j.heliyon.2024.e26423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2024.e26423</ArticleId><ArticleId IdType="pmc">PMC10907543</ArticleId><ArticleId IdType="pubmed">38434363</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway E. The race for coronavirus vaccines: A graphical guide. Nature. 2020;580:576–577. doi: 10.1038/d41586-020-01221-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-01221-y</ArticleId><ArticleId IdType="pubmed">32346146</ArticleId></ArticleIdList></Reference><Reference><Citation>World Healt Organization  COVID-19 Vaccination Insights Report—4 March 2024.  [(accessed on 5 August 2024)].  Available online:  https://www.who.int/publications/m/item/covid-19-vaccination-insights-report-4-march-2024.</Citation></Reference><Reference><Citation>Instituto Nacional de Salud  COVID-19 en Colombia.  [(accessed on 5 August 2024)]; Available online:  https://www.ins.gov.co/Noticias/Paginas/coronavirus-genoma.aspx.</Citation></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271–280.e8. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444–1448. doi: 10.1126/science.abb2762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb2762</ArticleId><ArticleId IdType="pmc">PMC7164635</ArticleId><ArticleId IdType="pubmed">32132184</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahid M., Jawed A., Mandal R.K., Areeshi M.Y., El-Shall N.A., Mohapatra R.K., Tuli H.S., Dhama K., Pellicano R., Fagoonee S., et al. Role of available COVID-19 vaccines in reducing deaths and perspective for next generation vaccines and therapies to counter emerging viral variants: An update. Minerva Med. 2023;114:683–697. doi: 10.23736/S0026-4806.23.08509-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S0026-4806.23.08509-9</ArticleId><ArticleId IdType="pubmed">37293890</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam M.A. A review of SARS-CoV-2 variants and vaccines: Viral properties, mutations, vaccine efficacy, and safety. Infect. Med. 2023;2:247–261. doi: 10.1016/j.imj.2023.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imj.2023.08.005</ArticleId><ArticleId IdType="pmc">PMC10774670</ArticleId><ArticleId IdType="pubmed">38205179</ArticleId></ArticleIdList></Reference><Reference><Citation>Markov P.V., Ghafari M., Beer M., Lythgoe K., Simmonds P., Stilianakis N.I., Katzourakis A. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 2023;21:361–379. doi: 10.1038/s41579-023-00878-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00878-2</ArticleId><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., Sivan M., Perlowski A., Nikolich J.Ž. Long COVID: A clinical update. Lancet. 2024;404:707–724. doi: 10.1016/S0140-6736(24)01136-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(24)01136-X</ArticleId><ArticleId IdType="pubmed">39096925</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z. SARS-CoV-2 antivirals and post-COVID-19 condition. Lancet Infect. Dis. 2024. in press .</Citation><ArticleIdList><ArticleId IdType="pubmed">39265592</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris V., Holmes J., Gbinigie-Thompson O., Rahman N.M., Richards D.B., Hayward G., Dorward J., Lowe D.M., Standing J.F., Breuer J., et al. Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): A randomised controlled trial. Lancet Infect. Dis. 2024. in press .</Citation><ArticleIdList><ArticleId IdType="pubmed">39265595</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu S., Chakravarty D., Bhattacharyya D., Saha P., Patra H.K. Plausible blockers of Spike RBD in SARS-CoV-2-molecular design and underlying interaction dynamics from high-level structural descriptors. J. Mol. Model. 2021;27:191. doi: 10.1007/s00894-021-04779-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00894-021-04779-0</ArticleId><ArticleId IdType="pmc">PMC8165686</ArticleId><ArticleId IdType="pubmed">34057647</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y.W., Xie Y., Tang L.S., Pu D., Zhu Y.J., Liu J.Y., Ma X.L. Therapeutic targets and interventional strategies in COVID-19: Mechanisms and clinical studies. Signal Transduct. Target. Ther. 2021;6:317. doi: 10.1038/s41392-021-00733-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00733-x</ArticleId><ArticleId IdType="pmc">PMC8390046</ArticleId><ArticleId IdType="pubmed">34446699</ArticleId></ArticleIdList></Reference><Reference><Citation>Schutz D., Ruiz-Blanco Y.B., Munch J., Kirchhoff F., Sanchez-Garcia E., Muller J.A. Peptide and peptide-based inhibitors of SARS-CoV-2 entry. Adv. Drug Deliv. Rev. 2020;167:47–65. doi: 10.1016/j.addr.2020.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2020.11.007</ArticleId><ArticleId IdType="pmc">PMC7665879</ArticleId><ArticleId IdType="pubmed">33189768</ArticleId></ArticleIdList></Reference><Reference><Citation>Helmer D., Schmitz K. Peptides and Peptide Analogs to Inhibit Protein-Protein Interactions. Adv. Exp. Med. Biol. 2016;917:147–183.</Citation><ArticleIdList><ArticleId IdType="pubmed">27236556</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah J.N., Guo G.Q., Krishnan A., Ramesh M., Katari N.K., Shahbaaz M., Abdellattif M.H., Singh S.K., Dua K. Peptides-based therapeutics: Emerging potential therapeutic agents for COVID-19. Therapie. 2022;77:319–328. doi: 10.1016/j.therap.2021.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.therap.2021.09.007</ArticleId><ArticleId IdType="pmc">PMC8498005</ArticleId><ArticleId IdType="pubmed">34689960</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmoudi Azar L., Oncel M.M., Karaman E., Soysal L.F., Fatima A., Choi S.B., Eyupoglu A.E., Erman B., Khan A.M., Uysal S. Human ACE2 orthologous peptide sequences show better binding affinity to SARS-CoV-2 RBD domain: Implications for drug design. Comput. Struct. Biotechnol. J. 2023;21:4096–4109. doi: 10.1016/j.csbj.2023.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2023.07.022</ArticleId><ArticleId IdType="pmc">PMC10475354</ArticleId><ArticleId IdType="pubmed">37671240</ArticleId></ArticleIdList></Reference><Reference><Citation>Odolczyk N., Klim J., Podsiadla-Bialoskorska M., Winiewska-Szajewska M., Szolajska E., Zielenkiewicz U., Poznanski J., Zielenkiewicz P. Improvement of native structure-based peptides as efficient inhibitors of protein-protein interactions of SARS-CoV-2 spike protein and human ACE2. Front. Mol. Biosci. 2022;9:983014. doi: 10.3389/fmolb.2022.983014.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2022.983014</ArticleId><ArticleId IdType="pmc">PMC9555309</ArticleId><ArticleId IdType="pubmed">36250011</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumon T.A., Hussain M.A., Hasan M.T., Hasan M., Jang W.J., Bhuiya E.H., Chowdhury A.A.M., Sharifuzzaman S.M., Brown C.L., Kwon H.J., et al. A Revisit to the Research Updates of Drugs, Vaccines, and Bioinformatics Approaches in Combating COVID-19 Pandemic. Front. Mol. Biosci. 2020;7:585899. doi: 10.3389/fmolb.2020.585899.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2020.585899</ArticleId><ArticleId IdType="pmc">PMC7868442</ArticleId><ArticleId IdType="pubmed">33569389</ArticleId></ArticleIdList></Reference><Reference><Citation>Hufsky F., Lamkiewicz K., Almeida A., Aouacheria A., Arighi C., Bateman A., Baumbach J., Beerenwinkel N., Brandt C., Cacciabue M., et al. Computational strategies to combat COVID-19: Useful tools to accelerate SARS-CoV-2 and coronavirus research. Brief. Bioinform. 2021;22:642–663. doi: 10.1093/bib/bbaa232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbaa232</ArticleId><ArticleId IdType="pmc">PMC7665365</ArticleId><ArticleId IdType="pubmed">33147627</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei C.R., Basharat Z., Lang’at G.C. In Silico Therapeutic Study: The Next Frontier in the Fight against SARS-CoV-2 and Its Variants. Drugs Drug Candidates. 2024;3:54–69. doi: 10.3390/ddc3010005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ddc3010005</ArticleId></ArticleIdList></Reference><Reference><Citation>Alméciga-Díaz C.J., Pimentel-Vera L.N., Caro A., Mosquera A., Castellanos Moreno C.A., Manosalva Rojas J.P., Díaz-Tribaldos D.C. Virtual Screening of Potential Inhibitors for SARS-CoV-2 Main Protease. Preprints. 2020:2020040146. doi: 10.20944/preprints202004.0146.v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.20944/preprints202004.0146.v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S., Florez H. Bioinformatic study to discover natural molecules with activity against COVID-19 [version 1; peer review: 2 approved] F1000Research. 2020;9:1–14. doi: 10.12688/f1000research.26731.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.26731.1</ArticleId><ArticleId IdType="pmc">PMC7590895</ArticleId><ArticleId IdType="pubmed">33145015</ArticleId></ArticleIdList></Reference><Reference><Citation>Yañez O., Osorio M.I., Uriarte E., Areche C., Tiznado W., Pérez-Donoso J.M., García-Beltrán O., González-Nilo F. In Silico Study of Coumarins and Quinolines Derivatives as Potent Inhibitors of SARS-CoV-2 Main Protease. Front. Chem. 2021;8:595097. doi: 10.3389/fchem.2020.595097.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2020.595097</ArticleId><ArticleId IdType="pmc">PMC7893092</ArticleId><ArticleId IdType="pubmed">33614592</ArticleId></ArticleIdList></Reference><Reference><Citation>Zapata-Cardona M.I., Florez-Alvarez L., Guerra-Sandoval A.L., Chvatal-Medina M., Guerra-Almonacid C.M., Hincapie-Garcia J., Hernandez J.C., Rugeles M.T., Zapata-Builes W. In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach. AIMS Microbiol. 2023;9:20–40. doi: 10.3934/microbiol.2023002.</Citation><ArticleIdList><ArticleId IdType="doi">10.3934/microbiol.2023002</ArticleId><ArticleId IdType="pmc">PMC9988408</ArticleId><ArticleId IdType="pubmed">36891537</ArticleId></ArticleIdList></Reference><Reference><Citation>Osorio M.I., Yáñez O., Gallardo M., Zuñiga-Bustos M., Mulia-Rodríguez J., López-Rendón R., García-Beltrán O., González-Nilo F., Pérez-Donoso J.M. Search for Novel Potent Inhibitors of the SARS-CoV-2 Papain-like Enzyme: A Computational Biochemistry Approach. Pharmaceuticals. 2022;15:986. doi: 10.3390/ph15080986.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph15080986</ArticleId><ArticleId IdType="pmc">PMC9414997</ArticleId><ArticleId IdType="pubmed">36015134</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez C.A., Puertas P.G. Proteínas Miniace 2 Solubles Que Interaccionan Con SARS-CoV-2 y Usos de las Mismas. NC2022/0005322. 2023 May 5;</Citation></Reference><Reference><Citation>Nagae M., Yamaguchi Y. Function and 3D structure of the N-glycans on glycoproteins. Int. J. Mol. Sci. 2012;13:8398–8429. doi: 10.3390/ijms13078398.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms13078398</ArticleId><ArticleId IdType="pmc">PMC3430242</ArticleId><ArticleId IdType="pubmed">22942711</ArticleId></ArticleIdList></Reference><Reference><Citation>Landázuri P., Poutou-Piñales R.A., Acero-Godoy J., Córdoba-Ruiz H., Echeverri-Peña O.Y., Sáenz H., Delgado J., Barrera-Avellaneda L.A. Cloning and shake flask expression of hrIDS-Like in Pichia pastoris. Afr. J. Biotechnol. 2009;8:2871–2877.</Citation></Reference><Reference><Citation>Pimentel N., Rodríguez-Lopez A., Díaz S., Losada J.C., Díaz-Rincón D.J., Cardona C., Espejo-Mojica Á., Ramírez A.M., Ruiz F., Landázuri P., et al. Production and characterization of a human lysosomal recombinant iduronate-2-sulfatase produced in Pichia pastoris. Biotechnol. Appl. Biochem. 2018;65:655–664. doi: 10.1002/bab.1660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bab.1660</ArticleId><ArticleId IdType="pubmed">29633336</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu M., Li R., Baskfield A., Lu B., Farkhondeh A., Gorshkov K., Motabar O., Beers J., Chen G., Zou J., et al. Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease. Orphanet J. Rare Dis. 2018;13:152. doi: 10.1186/s13023-018-0886-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-018-0886-3</ArticleId><ArticleId IdType="pmc">PMC6139903</ArticleId><ArticleId IdType="pubmed">30220252</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Lopez A., Almeciga-Diaz C.J., Sanchez J., Moreno J., Beltran L., Diaz D., Pardo A., Ramirez A.M., Espejo-Mojica A.J., Pimentel L., et al. Recombinant human N-acetylgalactosamine-6-sulfate sulfatase (GALNS) produced in the methylotrophic yeast Pichia pastoris. Sci. Rep. 2016;6:29329. doi: 10.1038/srep29329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep29329</ArticleId><ArticleId IdType="pmc">PMC4932491</ArticleId><ArticleId IdType="pubmed">27378276</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Lopez A., Pimentel-Vera L.N., Espejo-Mojica A.J., Van H.A., Tiels P., Tomatsu S., Callewaert N., Almeciga-Diaz C.J. Characterization of human recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in Pichia pastoris as potential enzyme for mucopolysaccharidosis IVA treatment. J. Pharm. Sci. 2019;108:2534–2541. doi: 10.1016/j.xphs.2019.03.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2019.03.034</ArticleId><ArticleId IdType="pubmed">30959056</ArticleId></ArticleIdList></Reference><Reference><Citation>Espejo-Mojica A.J., Mosquera A., Rodrfguez-Lopez A., Diaz D., Beltran L., Hernandez F.L., Alméciga-Diaz C.J., Barrera L.A. Characterization of recombinant human lysosomal beta-hexosaminidases produced in the methylotrophic yeast Pichia pastoris. Univ. Sci. 2016;21:195–217. doi: 10.11144/Javeriana.SC21-3.corh.</Citation><ArticleIdList><ArticleId IdType="doi">10.11144/Javeriana.SC21-3.corh</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarado-Obando M., Contreras N., Leon D., Botero L., Beltran L., Diaz D., Rodriguez-Lopez A., Reyes L.H., Almeciga-Diaz C.J., Sanchez O.F. Engineering a heterologously expressed fructosyltransferase from Aspergillus oryzae N74 in Komagataella phaffii (Pichia pastoris) for kestose production. New Biotechnol. 2022;69:18–27. doi: 10.1016/j.nbt.2022.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbt.2022.02.005</ArticleId><ArticleId IdType="pubmed">35217201</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Rincon D.J., Duque I., Osorio E., Rodriguez-Lopez A., Espejo-Mojica A., Parra-Giraldo C.M., Poutou-Pinales R.A., Almeciga-Diaz C.J., Quevedo-Hidalgo B. Production of Recombinant Trichoderma reesei Cellobiohydrolase II in a New Expression System Based on Wickerhamomyces anomalus. Enzym. Res. 2017;2017:6980565. doi: 10.1155/2017/6980565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/6980565</ArticleId><ArticleId IdType="pmc">PMC5603120</ArticleId><ArticleId IdType="pubmed">28951785</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintero Barbosa J.S., Rojas H.Y.T., Gonzalez J., Espejo-Mojica A.J., Diaz C.J.A., Gutierrez M.F. Characterization and expression of domains of Alphaherpesvirus bovine 1/5 envelope glycoproteins B in Komagataella phaffi. BMC Vet. Res. 2023;19:28. doi: 10.1186/s12917-023-03590-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12917-023-03590-8</ArticleId><ArticleId IdType="pmc">PMC9887784</ArticleId><ArticleId IdType="pubmed">36721143</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintero Barbosa J.S., Almeciga-Diaz C.J., Perez S.E., Gutierrez M.F. Humoral Immune Response of Mice against a Vaccine Candidate Composed of a Chimera of gB of Bovine Alphaherpesviruses 1 and 5. Vaccines. 2023;11:1173. doi: 10.3390/vaccines11071173.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11071173</ArticleId><ArticleId IdType="pmc">PMC10386439</ArticleId><ArticleId IdType="pubmed">37514988</ArticleId></ArticleIdList></Reference><Reference><Citation>Sievers F., Wilm A., Dineen D., Gibson T.J., Karplus K., Li W., Lopez R., McWilliam H., Remmert M., Soding J., et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 2011;7:539. doi: 10.1038/msb.2011.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/msb.2011.75</ArticleId><ArticleId IdType="pmc">PMC3261699</ArticleId><ArticleId IdType="pubmed">21988835</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannan S.R., Spratt A.N., Cohen A.R., Naqvi S.H., Chand H.S., Quinn T.P., Lorson C.L., Byrareddy S.N., Singh K. Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses. J. Autoimmun. 2021;124:102715. doi: 10.1016/j.jaut.2021.102715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102715</ArticleId><ArticleId IdType="pmc">PMC8354793</ArticleId><ArticleId IdType="pubmed">34399188</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha L.B., Foster C., Rawlinson W., Tedla N., Bull R.A. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. Rev. Med. Virol. 2022;32:e2381. doi: 10.1002/rmv.2381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2381</ArticleId><ArticleId IdType="pmc">PMC9349777</ArticleId><ArticleId IdType="pubmed">35856385</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghafari M., Hall M., Golubchik T., Ayoubkhani D., House T., MacIntyre-Cockett G., Fryer H.R., Thomson L., Nurtay A., Kemp S.A., et al. Prevalence of persistent SARS-CoV-2 in a large community surveillance study. Nature. 2024;626:1094–1101. doi: 10.1038/s41586-024-07029-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-024-07029-4</ArticleId><ArticleId IdType="pmc">PMC10901734</ArticleId><ArticleId IdType="pubmed">38383783</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossino G., Marchese E., Galli G., Verde F., Finizio M., Serra M., Linciano P., Collina S. Peptides as Therapeutic Agents: Challenges and Opportunities in the Green Transition Era. Molecules. 2023;28:1272. doi: 10.3390/molecules28207165.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules28207165</ArticleId><ArticleId IdType="pmc">PMC10609221</ArticleId><ArticleId IdType="pubmed">37894644</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr T.N., Zepeda S.K., Walls A.C., Greaney A.J., Alkhovsky S., Veesler D., Bloom J.D. ACE2 binding is an ancestral and evolvable trait of sarbecoviruses. Nature. 2022;603:913–918. doi: 10.1038/s41586-022-04464-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04464-z</ArticleId><ArticleId IdType="pmc">PMC8967715</ArticleId><ArticleId IdType="pubmed">35114688</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23:3–20. doi: 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q., Zhang L., et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215–220. doi: 10.1038/s41586-020-2180-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2180-5</ArticleId><ArticleId IdType="pubmed">32225176</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah V.K., Firmal P., Alam A., Ganguly D., Chattopadhyay S. Overview of Immune Response during SARS-CoV-2 Infection: Lessons From the Past. Front. Immunol. 2020;11:1949. doi: 10.3389/fimmu.2020.01949.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01949</ArticleId><ArticleId IdType="pmc">PMC7426442</ArticleId><ArticleId IdType="pubmed">32849654</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S., Zhu Y., Liu M., Lan Q., Xu W., Wu Y., Ying T., Liu S., Shi Z., Jiang S., et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell. Mol. Immunol. 2020;17:765–767. doi: 10.1038/s41423-020-0374-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0374-2</ArticleId><ArticleId IdType="pmc">PMC7075278</ArticleId><ArticleId IdType="pubmed">32047258</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D., McConnell S., Casadevall A., Cappello E., Valdiserra G., Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect. Dis. 2022;22:e311–e326. doi: 10.1016/S1473-3099(22)00311-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00311-5</ArticleId><ArticleId IdType="pmc">PMC9255948</ArticleId><ArticleId IdType="pubmed">35803289</ArticleId></ArticleIdList></Reference><Reference><Citation>Baum A., Fulton B.O., Wloga E., Copin R., Pascal K.E., Russo V., Giordano S., Lanza K., Negron N., Ni M., et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014–1018. doi: 10.1126/science.abd0831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd0831</ArticleId><ArticleId IdType="pmc">PMC7299283</ArticleId><ArticleId IdType="pubmed">32540904</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojadzic D., Alcazar O., Chen J., Chuang S.T., Condor Capcha J.M., Shehadeh L.A., Buchwald P. Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2. ACS Infect. Dis. 2021;7:1519–1534. doi: 10.1021/acsinfecdis.1c00070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.1c00070</ArticleId><ArticleId IdType="pmc">PMC8130611</ArticleId><ArticleId IdType="pubmed">33979123</ArticleId></ArticleIdList></Reference><Reference><Citation>Panchal D., Kataria J., Patel K., Crowe K., Pai V., Azizogli A.-R., Kadian N., Sanyal S., Roy A., Dodd-o J., et al. Peptide-Based Inhibitors for SARS-CoV-2 and SARS-CoV. Adv. Ther. 2021;4:2100104. doi: 10.1002/adtp.202100104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adtp.202100104</ArticleId><ArticleId IdType="pmc">PMC8420164</ArticleId><ArticleId IdType="pubmed">34514085</ArticleId></ArticleIdList></Reference><Reference><Citation>Karoyan P., Vieillard V., Gómez-Morales L., Odile E., Guihot A., Luyt C.-E., Denis A., Grondin P., Lequin O. Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection. Commun. Biol. 2021;4:197. doi: 10.1038/s42003-021-01736-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-01736-8</ArticleId><ArticleId IdType="pmc">PMC7881012</ArticleId><ArticleId IdType="pubmed">33580154</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Chen L., Qin S., Xie M., Luo S.Z., Li W. Advances in biosynthesis of peptide drugs: Technology and industrialization. Biotechnol. J. 2024;19:e2300256. doi: 10.1002/biot.202300256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biot.202300256</ArticleId><ArticleId IdType="pubmed">37884278</ArticleId></ArticleIdList></Reference><Reference><Citation>Raschmanova H., Weninger A., Knejzlik Z., Melzoch K., Kovar K. Engineering of the unfolded protein response pathway in Pichia pastoris: Enhancing production of secreted recombinant proteins. Appl. Microbiol. Biotechnol. 2021;105:4397–4414. doi: 10.1007/s00253-021-11336-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-021-11336-5</ArticleId><ArticleId IdType="pmc">PMC8195892</ArticleId><ArticleId IdType="pubmed">34037840</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C., Gong J.S., Su C., Li H., Li H., Rao Z.M., Xu Z.H., Shi J.S. Pathway engineering facilitates efficient protein expression in Pichia pastoris. Appl. Microbiol. Biotechnol. 2022;106:5893–5912. doi: 10.1007/s00253-022-12139-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-022-12139-y</ArticleId><ArticleId IdType="pubmed">36040488</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai H., Zhang C., Wu J., Tang Q., Xie Y., Yu Y., Lin Y., Huang Y. Optimizing Pichia pastoris protein secretion: Role of N-linked glycosylation on the alpha-mating factor secretion signal leader. J. Biotechnol. 2024;391:1–10. doi: 10.1016/j.jbiotec.2024.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbiotec.2024.04.008</ArticleId><ArticleId IdType="pubmed">38636846</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou C., Lu L., Wang S., Zhang C., Chen X., Lin Y., Huang Y. The alpha-mating factor secretion signals and endogenous signal peptides for recombinant protein secretion in Komagataella phaffii. Biotechnol. Biofuels Bioprod. 2022;15:140. doi: 10.1186/s13068-022-02243-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13068-022-02243-6</ArticleId><ArticleId IdType="pmc">PMC9756452</ArticleId><ArticleId IdType="pubmed">36527112</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta R., Brunak S. Prediction of glycosylation across the human proteome and the correlation to protein function. Biocomputing. 2001;2002:310–322.</Citation><ArticleIdList><ArticleId IdType="pubmed">11928486</ArticleId></ArticleIdList></Reference><Reference><Citation>Raschmanova H., Zamora I., Borcinova M., Meier P., Weninger A., Machler D., Glieder A., Melzoch K., Knejzlik Z., Kovar K. Single-Cell Approach to Monitor the Unfolded Protein Response during Biotechnological Processes with Pichia pastoris. Front. Microbiol. 2019;10:335. doi: 10.3389/fmicb.2019.00335.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.00335</ArticleId><ArticleId IdType="pmc">PMC6404689</ArticleId><ArticleId IdType="pubmed">30873140</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldwell S.R., Hill K.J., Cooper A.A. Degradation of endoplasmic reticulum (ER) quality control substrates requires transport between the ER and Golgi. J. Biol. Chem. 2001;276:23296–23303. doi: 10.1074/jbc.M102962200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M102962200</ArticleId><ArticleId IdType="pubmed">11316816</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Skolnick J. TM-align: A protein structure alignment algorithm based on the TM-score. Nucleic Acids Res. 2005;33:2302–2309. doi: 10.1093/nar/gki524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gki524</ArticleId><ArticleId IdType="pmc">PMC1084323</ArticleId><ArticleId IdType="pubmed">15849316</ArticleId></ArticleIdList></Reference><Reference><Citation>Duong D. Alpha, Beta, Delta, Gamma: What’s important to know about SARS-CoV-2 variants of concern? CMAJ. 2021;193:E1059–E1060. doi: 10.1503/cmaj.1095949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.1095949</ArticleId><ArticleId IdType="pmc">PMC8342008</ArticleId><ArticleId IdType="pubmed">34253551</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou J., Lan W., Wu X., Zhao T., Duan B., Yang P., Ren Y., Quan L., Zhao W., Seto D., et al. Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events. Signal Transduct. Target. Ther. 2022;7:138. doi: 10.1038/s41392-022-00992-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00992-2</ArticleId><ArticleId IdType="pmc">PMC9039610</ArticleId><ArticleId IdType="pubmed">35474215</ArticleId></ArticleIdList></Reference><Reference><Citation>da Costa C.H.S., de Freitas C.A.B., Alves C.N., Lameira J. Assessment of mutations on RBD in the Spike protein of SARS-CoV-2 Alpha, Delta and Omicron variants. Sci. Rep. 2022;12:8540. doi: 10.1038/s41598-022-12479-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-12479-9</ArticleId><ArticleId IdType="pmc">PMC9121086</ArticleId><ArticleId IdType="pubmed">35595778</ArticleId></ArticleIdList></Reference><Reference><Citation>Argentinian AntiCovid C. Structural and functional comparison of SARS-CoV-2-spike receptor binding domain produced in Pichia pastoris and mammalian cells. Sci. Rep. 2020;10:21779. doi: 10.1038/s41598-020-78711-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-78711-6</ArticleId><ArticleId IdType="pmc">PMC7732851</ArticleId><ArticleId IdType="pubmed">33311634</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Yao X., Tsang S.Y. Post-Translational Modification and Natural Mutation of TRPC Channels. Cells. 2020;9:135. doi: 10.3390/cells9010135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9010135</ArticleId><ArticleId IdType="pmc">PMC7016788</ArticleId><ArticleId IdType="pubmed">31936014</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh G., Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat. Biotechnol. 2006;24:1241–1252. doi: 10.1038/nbt1252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt1252</ArticleId><ArticleId IdType="pubmed">17033665</ArticleId></ArticleIdList></Reference><Reference><Citation>Miguez-Rey E., Choi D., Kim S., Yoon S., Sandulescu O. Monoclonal antibody therapies in the management of SARS-CoV-2 infection. Expert Opin. Investig. Drugs. 2022;31:41–58. doi: 10.1080/13543784.2022.2030310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543784.2022.2030310</ArticleId><ArticleId IdType="pmc">PMC8862171</ArticleId><ArticleId IdType="pubmed">35164631</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiros-Roldan E., Amadasi S., Zanella I., Degli Antoni M., Storti S., Tiecco G., Castelli F. Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives. Pharmaceuticals. 2021;14:1272. doi: 10.3390/ph14121272.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14121272</ArticleId><ArticleId IdType="pmc">PMC8707981</ArticleId><ArticleId IdType="pubmed">34959672</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins M.R., Gasteiger E., Bairoch A., Sanchez J.C., Williams K.L., Appel R.D., Hochstrasser D.F. Protein identification and analysis tools in the ExPASy server. Methods Mol. Biol. 1999;112:531–552.</Citation><ArticleIdList><ArticleId IdType="pubmed">10027275</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramson J., Adler J., Dunger J., Evans R., Green T., Pritzel A., Ronneberger O., Willmore L., Ballard A.J., Bambrick J., et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630:493–500. doi: 10.1038/s41586-024-07487-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-024-07487-w</ArticleId><ArticleId IdType="pmc">PMC11168924</ArticleId><ArticleId IdType="pubmed">38718835</ArticleId></ArticleIdList></Reference><Reference><Citation>De Wachter C., Van Landuyt L., Callewaert N. Engineering of Yeast Glycoprotein Expression. In: Rapp E., Reichl U., editors. Advances in Glycobiotechnology. Springer International Publishing; Cham, Switzerland: 2021. pp. 93–135.</Citation><ArticleIdList><ArticleId IdType="pubmed">30397726</ArticleId></ArticleIdList></Reference><Reference><Citation>Vangone A., Bonvin A.M. Contacts-based prediction of binding affinity in protein-protein complexes. eLife. 2015;4:e07454. doi: 10.7554/eLife.07454.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.07454</ArticleId><ArticleId IdType="pmc">PMC4523921</ArticleId><ArticleId IdType="pubmed">26193119</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez G., Chow J., Bongen P., Lauinger B., Pietruszka J., Streit W.R., Baena S. A novel thermoalkalostable esterase from Acidicaldus sp. strain USBA-GBX-499 with enantioselectivity isolated from an acidic hot springs of Colombian Andes. Appl. Microbiol. Biotechnol. 2014;98:8603–8616. doi: 10.1007/s00253-014-5775-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-014-5775-7</ArticleId><ArticleId IdType="pubmed">24818691</ArticleId></ArticleIdList></Reference><Reference><Citation>Ausubel F.M., Brent R., Kingston R.E., Moore D.D. Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology. 4th ed. Wiley; Hoboken, NJ, USA: 1999.</Citation></Reference><Reference><Citation>Schneider C.A., Rasband W.S., Eliceiri K.W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods. 2012;9:671–675. doi: 10.1038/nmeth.2089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2089</ArticleId><ArticleId IdType="pmc">PMC5554542</ArticleId><ArticleId IdType="pubmed">22930834</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Guo Y., Iketani S., Nair M.S., Li Z., Mohri H., Wang M., Yu J., Bowen A.D., Chang J.Y., et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature. 2022;608:603–608. doi: 10.1038/s41586-022-05053-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05053-w</ArticleId><ArticleId IdType="pmc">PMC9385487</ArticleId><ArticleId IdType="pubmed">35790190</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q., Wu L., Xu Z., Wang X., Xie Y., Chai Y., Zheng A., Zhou J., Qiao S., Huang M., et al. An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB. Cell Rep. Med. 2023;4:100991. doi: 10.1016/j.xcrm.2023.100991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2023.100991</ArticleId><ArticleId IdType="pmc">PMC10027947</ArticleId><ArticleId IdType="pubmed">37019110</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans R.A., Dube S., Lu Y., Yates M., Arnetorp S., Barnes E., Bell S., Carty L., Evans K., Graham S., et al. Impact of COVID-19 on immunocompromised populations during the Omicron era: Insights from the observational population-based INFORM study. Lancet Reg. Health Eur. 2023;35:100747. doi: 10.1016/j.lanepe.2023.100747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2023.100747</ArticleId><ArticleId IdType="pmc">PMC10730312</ArticleId><ArticleId IdType="pubmed">38115964</ArticleId></ArticleIdList></Reference><Reference><Citation>Antinori A., Bausch-Jurken M. The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future. J. Infect. Dis. 2023;228((Suppl. S1)):S4–S12. doi: 10.1093/infdis/jiad181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad181</ArticleId><ArticleId IdType="pmc">PMC10401620</ArticleId><ArticleId IdType="pubmed">37539764</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>